These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 20929376)

  • 1. Progress and challenges in implementing the research on ESKAPE pathogens.
    Rice LB
    Infect Control Hosp Epidemiol; 2010 Nov; 31 Suppl 1():S7-10. PubMed ID: 20929376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of the ESKAPE pathogens.
    Pendleton JN; Gorman SP; Gilmore BF
    Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
    Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
    Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview perspective of bacterial resistance.
    Furtado GH; Nicolau DP
    Expert Opin Ther Pat; 2010 Oct; 20(10):1273-6. PubMed ID: 20687782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico.
    Llaca-Díaz JM; Mendoza-Olazarán S; Camacho-Ortiz A; Flores S; Garza-González E
    Chemotherapy; 2012; 58(6):475-81. PubMed ID: 23548324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESKAPEing the labyrinth of antibacterial discovery.
    Tommasi R; Brown DG; Walkup GK; Manchester JI; Miller AA
    Nat Rev Drug Discov; 2015 Aug; 14(8):529-42. PubMed ID: 26139286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogens resistant to antibacterial agents.
    Chen LF; Chopra T; Kaye KS
    Infect Dis Clin North Am; 2009 Dec; 23(4):817-45, vii. PubMed ID: 19909886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
    Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
    Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
    Santajit S; Indrawattana N
    Biomed Res Int; 2016; 2016():2475067. PubMed ID: 27274985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
    Behroozian S; Svensson SL; Davies J
    mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.
    Adam HJ; DeCorby M; Rennie R; Karlowsky JA; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):307-13. PubMed ID: 21353958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities.
    Wisplinghoff H; Seifert H; Tallent SM; Bischoff T; Wenzel RP; Edmond MB
    Pediatr Infect Dis J; 2003 Aug; 22(8):686-91. PubMed ID: 12913767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.